Sartorius $90m IntelliCyt acquisition adds cell analysis capabilities

By Dan Stanton contact

- Last updated on GMT

Image: iStock/pichet_w
Image: iStock/pichet_w

Related tags: Contract research organization

Sartorius has expanded its bio-analytics capabilities through the $90m (€81m) acquisition of IntelliCyt.

The deal sees Germany’s Sartorius bolster its lab products and services division, adding Albuquerque, New Mexico instrumentation, software and reagent firm IntelliCyt.

“Sartorius is already present in [the bio-analytics] market with its broad lab portfolio for sample preparation,”​ Sartorius spokesperson Petra Kirchhoff told Biopharma-Reporter.com. “This is a further step that will especially enhance our presence with scientists who work in the pharmaceutical and biotech industries as well as academia.”

The deal includes IntelliCyt’s I Que Screener platform which is based on cytometry, according to Kirchhoff, integrates instruments, software and reagents to enable rapid, high-throughput cell analysis for assessing multiple cellular parameters.

“The I Que Screener also minimises sample size requirements, while making it possible to deliver content-rich results in just minutes. As sample preparation is simple, it is also possible to trace cell reactions right from the very beginning.”

M&A strategy

Sartorius has traditionally been a bioprocessing equipment and solutions firm, and about 74% of its revenues still come from this division, which focuses on single-use products for the manufacture of biopharmaceuticals.

But the firm is also pursuing a diversification programme to help grow the business, which has seen such acquisitions in its Lab Products & Services Division as the contract research organisation (CRO) BioOutsource, which it bought last year​ adding biopharma testing services including safety monitoring, drug characterisation and comparability testing of biologics and vaccines.

“We are following our Total Solution Provider Strategy for Biopharma already since more than a decade, and have recently addressed the earlier steps of the value chain,”​ said Kirchhoff, “so process development and the addition of IntelliCyt connects us with our clients even earlier in drug discovery.”

She added: “Complementary additions are possible in both our divisions, Bioprocess Solutions as well as Lab Products &Services.”

Related news

Show more

Related products

show more

Strategies for Upstream Intensification

Strategies for Upstream Intensification

Take the Right Path Upstream with MilliporeSigma | 01-Sep-2020 | Technical / White Paper

The Facility of the Future represents a transformation in how biologics are developed and manufactured.

Rapid Biosafety Testing Enables the Future of Manufacturing

Rapid Biosafety Testing Enables the Future of Manufacturing

Viral Safety for mAb: Prevent, Detect, Remove | 05-Aug-2020 | Technical / White Paper

Traditional methods for adventitious agent testing rely on biological amplification and detection, which can take several weeks. This time-consuming approach...

Related suppliers

Follow us

Products

View more

Webinars